Fluoxetine Tabs 60 mg approval solidifies the company's position in the molecule by complementing the recent approval in April 2024 for Fluoxetine 10 mg and 20 mg tablets and Fluoxetine capsules
The acquisition is based on an enterprise value of Rs. 1,660 crore
Investment in new plant meets increasing demand for functional excipients for oral drug delivery
The publication serves as a foundational tool for identifying gaps and addressing needs in various areas, including rural, urban, and tribal regions
The company has entered into a long-term lease and operations and management agreement with Sree Chand Specialty Hospital, situated in Kannur
This Fast Track Designation will enable FDA to review MM-II in an expedited manner, is an important milestone in the development of MM-II
Effective, holistic, science-backed targeted solutions for symptomatic treatment
New Phase II data show vast majority of patients experiencing no relapses or disability progression
Phase 3 study results will form the basis for future discussions with global regulatory authorities
MyClad is a global Phase III study evaluating the efficacy and safety of cladribine capsules for the treatment of generalized Myasthenia Gravis (gMG)
Subscribe To Our Newsletter & Stay Updated
